Andrew Nunn, Emeritus Professor of Epidemiology
Andrew Nunn worked as a statistician with Wallace Fox and Denny Mitchison as part of the team that conducted the landmark trials which led to the worldwide adoption of short-course chemotherapy for tuberculosis. In 1989 he joined the MRC's Uganda AIDS programme which investigated the dynamics of the HIV epidemic in a rural African setting. On returning to the UK, he joined the MRC Clinical Trials Unit at UCL with responsibility for the development of trials in neglected disease areas such as dermatology and respiratory medicine.
During his time at the MRC CTU at UCL, he led the TB research programme at the unit and was co-chief investigator on the STREAM trial, the first Phase III trial in multidrug-resistant TB.
As Emeritus Professor of Epidemiology, Andrew will continue to be available to contribute to the TB research programme.
Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. New England Journal of Medicine. 2023;388(10):873-887. DOI: 10.1056/NEJMoa2212537
Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. The Lancet. 2022;400(10366):1858-1868. DOI: https://doi.org/10.1016/S0140-6736(22)02078-5
Esmail H, Narendran G, Nunn A. Drug-resistant tuberculosis: Promising progress with a note of caution. The Indian Journal of Medical Research. 2022 DOI: 10.4103/ijmr.ijmr_677_22
Phillips PPJ, Van Deun A, Ahmed S, et al. Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. BMC Medicine. 2020/11/04 2020;18(1):314. doi:10.1186/s12916-020-01770-z
Lienhardt C, Nunn A, Chaisson R, et al. Advances in clinical trial design: Weaving tomorrow’s TB treatments. PLoS medicine. 2020;17(2):e1003059 DOI: https://doi.org/10.1371/journal.pmed.1003059
- Drug-sensitive tuberculosis
- Drug resistant tuberculosis